14109-1-AP

antibody from Proteintech Group

Targeting: SEPHS2 SPS2, SPS2b

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Antibody Data

Product number

14109-1-AP

Provider

Proteintech Group

Product name

SEPHS2 antibody

Antibody type

Polyclonal

Description

SEPHS2 antibody (Cat. #14109-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IHC, WB,ELISA.

Reactivity

Human, Mouse, Rat

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

20ul, 150ul

References

Submitted references

SEPHS2 loss reprograms cancer metabolism from oxidative phosphorylation to gluconeogenesis via PCK1 stabilization.

Zhang Y, Zhang Q, Wei B, Wang W, Chen X, Ding W, Li C, Ye Y, Xu J, Zhang W, Li L, Mai F, He W, Du X, Zhao K, Zhao Z, Huang J, Niu Y, Zhang Y, Dai L, Zhang B, Xia S
Cell reports 2026 Apr 25;45(5):117297

---

Macrophages and macrophage extracellular vesicles confer cancer ferroptosis resistance via PRDX6-mediated mitophagy inhibition.

Zheng N, Li F, Huang Q, Huang X, Maj T
Redox biology 2025 Oct;86:103826

---

Targeting VSMCs to suppress macrophage-like phenotype switching that restrains atherogenesis by immunosuppressive oligodeoxynucleotide (A151) functionalized selenium nanoparticles.

Wang J, Yao B, Zhang Y, Liu S, Liu W, Han Y, Shi K, Han W, Li R, Cai Z, Yang H, Ling Q, He J, Liu F, Gou S, Huang Z
Journal of nanobiotechnology 2025 Dec 15;24(1):54

---

METTL5 regulates SEPHS2-mediated selenoprotein synthesis to promote multiple myeloma survival and progression.

Jiang J, Zhong F, Xiao Z, Yao F, Liu J, Li M, Zeng H, Qiu Y, Zhang J, Zhang H, Li S, Huang T, Feng W, Huang Z, Huang B, Wang X
Cell death & disease 2025 Aug 2;16(1):585

---

Breast cancer secretes anti-ferroptotic MUFAs and depends on selenoprotein synthesis for metastasis.

Ackermann T, Shokry E, Deshmukh R, Anand J, Galbraith LCA, Mitchell L, Rodriguez-Blanco G, Villar VH, Sterken BA, Nixon C, Zanivan S, Blyth K, Sumpton D, Tardito S
EMBO molecular medicine 2024 Nov;16(11):2749-2774

---

H(2)Se-evolving bio-heterojunctions promote cutaneous regeneration in infected wounds by inhibiting excessive cellular senescence.

Yang F, Shu R, Dai W, Li B, Liu C, Yang H, Johnson HM, Yu S, Bai D, Yang W, Deng Y
Biomaterials 2024 Dec;311:122659

---

PRDX6 dictates ferroptosis sensitivity by directing cellular selenium utilization.

Ito J, Nakamura T, Toyama T, Chen D, Berndt C, Poschmann G, Mourão ASD, Doll S, Suzuki M, Zhang W, Zheng J, Trümbach D, Yamada N, Ono K, Yazaki M, Kawai Y, Arisawa M, Ohsaki Y, Shirakawa H, Wahida A, Proneth B, Saito Y, Nakagawa K, Mishima E, Conrad M
Molecular cell 2024 Dec 5;84(23):4629-4644.e9

---

PRDX6 augments selenium utilization to limit iron toxicity and ferroptosis.

Fujita H, Tanaka YK, Ogata S, Suzuki N, Kuno S, Barayeu U, Akaike T, Ogra Y, Iwai K
Nature structural & molecular biology 2024 Aug;31(8):1277-1285

---

A glycometabolic gene signature associating with immune infiltration and chemosensitivity and predicting the prognosis of patients with osteosarcoma.

Wang F, Yang K, Pan R, Xiang Y, Xiong Z, Li P, Li K, Sun H
Frontiers in medicine 2023;10:1115759